CAJ | 학술논문

目的:探讨多巴胺受体激动剂普拉克索对于不同时期帕金森综合征的临床疗效及安全性.方法:将本院收治的108例帕金森综合征患者随机分为普拉克索组及美多巴组,分别给予普拉克索及美多巴治疗,分别于治疗前及治疗4周、8周后采用帕金森评定量表第Ⅲ部分(UPDRSⅢ)对两组患者的临床疗效进行评价,并观察两组患者不良反应的发生情况.结果:两组患者治疗4周UPDRSⅢ评分比较,差异无统计学意义(P>0.05),而普拉克索组中晚期患者治疗8周后UPDRSⅢ评分显著低于美多巴组(P<0.05);普拉克索不良反应发生率显著低于美多巴组(P<0.05).结论:对于美多巴疗效较差的中晚期帕金森综合征患者,多巴胺受体激动剂能够达到良好的疗效,且安全性较高,值得临床推广应用.
목적:탐토다파알수체격동제보랍극색대우불동시기파금삼종합정적림상료효급안전성.방법:장본원수치적108례파금삼종합정환자수궤분위보랍극색조급미다파조,분별급여보랍극색급미다파치료,분별우치료전급치료4주、8주후채용파금삼평정량표제Ⅲ부분(UPDRSⅢ)대량조환자적림상료효진행평개,병관찰량조환자불량반응적발생정황.결과:량조환자치료4주UPDRSⅢ평분비교,차이무통계학의의(P>0.05),이보랍극색조중만기환자치료8주후UPDRSⅢ평분현저저우미다파조(P<0.05);보랍극색불량반응발생솔현저저우미다파조(P<0.05).결론:대우미다파료효교차적중만기파금삼종합정환자,다파알수체격동제능구체도량호적료효,차안전성교고,치득림상추엄응용.
Objective:To investigate the dopamine receptor agonist pramipexole for Parkinson’s syndrome,in different periods,clinical efficacy and safety. Method:108 cases of Parkinson’s syndrome patients were randomly divided into pramipexole group and US-dopa group,and were given pramipexole and US-dopa therapy. Before treatment and 4 weeks,8 weeks after the occurrence of Parkinson’s Rating Scale theⅢpart(UPDRSⅢ)to respectively evaluate the clinical efficacy of the two groups,and to observe the adverse reactions of the two groups,UPDRSⅢscore 4 weeks of treatment. Result:There were no significant differences(P>0.05),and pramipexole group after eight weeks of treatment in patients with advanced UPDRS Ⅲscore was significantly lower than that of the Madopar group(P<0.05). The pramipexole adverse occurrence rate was significantly lower than that of the US-dopa(P<0.05). Conclusion:For the less effective Madopa advanced Parkinson’s syndrome patients,dopamine receptor agonists to achieve good efficacy and high safety,is worthy of clinical application.